

JURISDICTION SPECIFIC MEDICARE PART B

FACTOR IX

REBINYN (coagulation factor IX [recombinant], glycoPEGylated)
IDELVION (coagulation factor IX [recombinant], albumin fusion protein)
ALPROLIX (coagulation factor IX [recombinant], Fc fusion protein)
BENEFIX, IXINITY, RIXUBIS (coagulation factor IX [recombinant])
ALPHANINE SD, MONONINE (coagulation factor IX [human])

POLICY

I. COVERED USES

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

Hemophilia B

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available in a legible format with patient identification information (e.g., complete name and dates of service) and signature of physician or non-physician practitioner responsible for and providing care to the member, upon request, for all submissions:

- A. The submitted medical record must support the use of the selected ICD-10-CM codes. The submitted CPT/HCPCS code must describe the service performed.
- B. The medical record documentation must support the medical necessity of the services as stated in this policy.

III. CRITERIA FOR APPROVAL

Hemophilia B

Authorization of 12 months may be granted for treatment of hemophilia B when the requested drug will be used for any of the following:

- A. Primary prophylactic therapy when the member has less than 1 percent of normal factor with the aim of keeping the factor IX level above 1 percent between doses.
- B. Continuous prophylactic therapy when the member does not have severe disease (greater than 1 percent of normal factor levels) and the member experiences repeated episodes of spontaneous bleeding.
- C. The requested drug will be used as on-demand treatment to control bleeding episodes.

Factor IX 4030-A MedB Jurisdiction H (AR CO LA MS NM OK TX) and L (DC DE MD NJ PA) P2022a.docx © 2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

IV. REFERENCES

1. Hemophilia Factor Products LCD (L35111) Version R16. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed December 15, 2021.
2. Billing and Coding: Hemophilia Factor Products (A56433) Version R7. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed December 15, 2021.
3. Alprolix [package insert]. Waltham, MA: Bioverativ Therapeutics, Inc.; October 2020.
4. BeneFIX [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; September 2021.
5. Ixinity [package insert]. Seattle, WA: Aptevo BioTherapeutics, LLC; February 2021.
6. Rixubis [package insert]. Lexington, MA: Baxalta US, Inc.; June 2020.
7. AlphaNine SD [package insert]. Los Angeles, CA: Grifols Biologicals LLC; February 2021.
8. Mononine [package insert]. Kankakee, IL: CSL Behring, LLC; December 2020.
9. Idelvion [package insert]. Kankakee, IL: CSL Behring, LLC; July 2021.
10. Rebinyn [package insert]. Plainsboro, NJ: Novo Nordisk, Inc.; June 2020.